Christine Lai, MD
Internal Medicine · Hot Springs, ARNPI 1427253889
Payments from drug & device makers
Across 238 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$591
- AstraZeneca$521
- AbbVie$402
- Amgen$378
- Dexcom, Inc.$297
- Astellas Pharma US Inc$275
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,64297%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $591 |
| AstraZeneca | 33 | $521 |
| AbbVie | 24 | $402 |
| Amgen | 25 | $378 |
| Dexcom, Inc. | 15 | $297 |
| Astellas Pharma US Inc | 13 | $275 |
| Lilly USA, LLC | 16 | $239 |
| Amarin Pharma, Inc. | 11 | $177 |
| Novartis | 12 | $173 |
| Pfizer | 8 | $131 |
| Boston Scientific | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 5 | $64 |
| Johnson & Johnson | 4 | $57 |
| Esperion Therapeutics, Inc. | 4 | $54 |
| Nestle Healthcare Nutrition Inc. | 3 | $51 |
| GSK | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Abbott | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Pacira Therapeutics, Inc. | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Inogen, Inc. | 2 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Boehringer Ingelheim | 1 | $12 |
| Philips North America LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$3,754 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $100,390 |
| JardianceEmpagliflozin | 57 | $60,230 |
| EliquisApixaban | 59 | $55,074 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $52,234 |
| UbrelvyUbrogepant | 11 | $35,214 |
| FarxigaDapagliflozin Propanediol | 33 | $22,173 |
| JanuviaSitagliptin Phosphate | 23 | $20,930 |
| XareltoRivaroxaban | 27 | $18,134 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $14,716 |
| QuliptaAtogepant | 11 | $13,640 |
| MyrbetriqMirabegron | 20 | $11,452 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,250 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 151 | $4,376 |
| Duloxetine Hcl | 111 | $4,353 |
| Varenicline Tartrate | 13 | $4,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $591 | $100,39096 claims |
| Boehringer IngelheimJardiance | $12 | $60,23057 claims |
| PfizerEliquis | $131 | $55,07459 claims |
| GSKTrelegy Ellipta | $47 | $52,23472 claims |
| AbbVieUbrelvy, Qulipta | $402 | $48,85422 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $521 | $29,42344 claims |
| Johnson & JohnsonXarelto | $57 | $18,13427 claims |
| Astellas Pharma US IncMyrbetriq | $275 | $11,45220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Hot Springs
- Jenny NavarroHot Springs$11K
- Seth BarnesHot Springs$9K
- James BridgesHot Springs$5K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Kathleen GannonRogers$450K
- Alexander KaczenskiLittle Rock$305K
- John HendersonSearcy$102K
- David PyleJonesboro$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.